Barclays Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $18
Baird Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $19
Owens & Minor Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Lexicon Pharmaceuticals (LXRX), Denali Therapeutics (DNLI) and Owens & Minor (OMI)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Merus (MRUS), Twist Bioscience (TWST) and Owens & Minor (OMI)
Owens & Minor Analyst Ratings
Barclays Maintains Equal-Weight on Owens & Minor, Lowers Price Target to $18
Barclays Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $18
Analysts Conflicted on These Healthcare Names: Owens & Minor (OMI), Tandem Diabetes Care (TNDM) and Alignment Healthcare (ALHC)
Analysts Conflicted on These Healthcare Names: Aquestive Therapeutics (AQST), Eli Lilly & Co (LLY) and Owens & Minor (OMI)
Market Perform Rating Maintained for Owens & Minor Amid Strategic Acquisitions and Financial Caution
Citi Maintains Owens & Minor(OMI.US) With Buy Rating
Citi Sticks to Their Buy Rating for Owens & Minor (OMI)
Barclays Maintains Owens & Minor(OMI.US) With Hold Rating, Maintains Target Price $23
Barclays Keeps Their Hold Rating on Owens & Minor (OMI)
Owens & Minor Analyst Ratings
Owens & Minor Analyst Ratings
Owens & Minor Analyst Ratings
Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)
Baird Adjusts Owens & Minor Price Target to $24 From $28, Maintains Neutral Rating